ReviewMedical oncology (Northwood, London, England)2025
Role of diosgenin in gastrointestinal cancers: recent trends and future perspectives.
Review in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastrointestinal cancers represent a considerable global public health burden, due to their high incidence, poor prognosis, and resistance to conventional therapies. Traditional treatments like chemotherapy and radiation often produce side effects and limited efficacy, making targeted therapies even more necessary. Diosgenin, a naturally steroidal saponin found in Dioscorea species, has gained widespread acclaim as an anticancer agent due to its anti-inflammatory, antioxidant, and cancer-fighting properties. This review presents an organ-specific assessment of diosgenin's anticancer properties against various gastrointestinal cancers, such as esophageal, gastric, colorectal, pancreatic, and liver. Although numerous reviews have addressed diosgenin's anticancer potential, ours stands out by offering an in-depth disease-specific mechanistic analysis, while taking advantage of recent advances in nanotechnology for optimizing its pharmacokinetics and bioavailability. Key highlights include diosgenin's synergistic interactions with cancer pathways such as Wnt/b-catenin, STAT3, and NF-kB-aspects not fully examined in previous reviews. Diosgenin's potential use in combination therapies with chemotherapeutics is also explored, including its clinical readiness as well as potential challenges such as bioavailability and solubility. Diosgenin has shown significant promise in preclinical studies; however, human cancer therapies require clinical trials to ascertain its safety and efficacy in human cancer treatments. This review offers a comprehensive perspective of diosgenin's mechanisms, nanomedicine innovations, and translational prospects-representing an essential step toward understanding its role in gastrointestinal cancers.
Indexed as
Identifiers
40751020What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.